O

Orion Oyj
OMXH:ORNBV

Watchlist Manager
Orion Oyj
OMXH:ORNBV
Watchlist
Price: 55.55 EUR 1.83%
Market Cap: 7.8B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ORNBV stock under the Base Case scenario is 59.15 EUR. Compared to the current market price of 55.55 EUR, Orion Oyj is Undervalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORNBV Relative Value
Base Case
59.15 EUR
Undervaluation 6%
Relative Value
Price
O
Worst Case
Base Case
Best Case

Valuation Multiples

4.9
P/S
P/S
Price to Sales
4.9
vs History
26
vs Industry
25
Median 3Y
4.6
Median 5Y
4.5
Industry
2.4
Forward
4.6
More Details
22.5
P/E
P/E
Price to Earnings
22.5
vs History
53
vs Industry
19
Median 3Y
22.3
Median 5Y
22.3
Industry
20.5
Forward
23.2
More Details
30
P/OCF
P/OCF
Price to OCF
30
vs History
17
vs Industry
15
Median 3Y
25.1
Median 5Y
21.7
Industry
15.6
More Details
26.4
P/FCFE
P/FCFE
Price to FCFE
26.4
vs History
44
vs Industry
19
Median 3Y
23.2
Median 5Y
24.5
Industry
23.1
More Details
7.3
P/B
P/B
Price to Book Value
7.3
vs History
36
vs Industry
8
Median 3Y
7.3
Median 5Y
6.9
Industry
2
More Details
4.9
EV/S
EV/S
Enterprise Value to Sales
4.9
vs History
22
vs Industry
24
Median 3Y
4.7
Median 5Y
4.5
Industry
2.5
Forward
4.7
More Details
8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8
vs History
42
vs Industry
25
Median 3Y
8
Median 5Y
7.8
Industry
4.9
More Details
17.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.8
vs History
44
vs Industry
19
Median 3Y
17.7
Median 5Y
16.6
Industry
12.3
Forward
17.3
More Details
17.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17.8
vs History
47
vs Industry
22
Median 3Y
17.7
Median 5Y
17.6
Industry
15.5
Forward
18.2
More Details
30
EV/OCF
EV/OCF
Enterprise Value to OCF
30
vs History
17
vs Industry
16
Median 3Y
25.2
Median 5Y
21.1
Industry
14.1
More Details
44
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
44
vs History
17
vs Industry
13
Median 3Y
36.9
Median 5Y
23.8
Industry
17.5
More Details
5.8
EV/IC
EV/IC
Enterprise Value to IC
5.8
vs History
34
vs Industry
13
Median 3Y
5.2
Median 5Y
5.5
Industry
1.8
More Details

Multiples Across Competitors

ORNBV Competitors Multiples
Orion Oyj Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
FI
Orion Oyj
OMXH:ORNBV
7.8B EUR 4.9 22.5 17.8 17.8
US
Eli Lilly and Co
NYSE:LLY
716.1B USD 14.6 64.5 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.8B USD 4.2 17 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.8 19.5 12.9 14.6
CH
Roche Holding AG
SIX:ROG
207.6B CHF 3.4 25.1 9.4 11
CH
Novartis AG
SIX:NOVN
179.1B CHF 4 16.5 9.8 13.1
UK
AstraZeneca PLC
LSE:AZN
159.9B GBP 3.8 27.1 130.3 196.5
US
Merck & Co Inc
NYSE:MRK
202.4B USD 3.2 11.6 8.6 10.5
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
131.3B USD 2.1 16.7 7.2 10.2
P/E Multiple
Earnings Growth PEG
FI
O
Orion Oyj
OMXH:ORNBV
Average P/E: 24.5
22.5
9%
2.5
US
Eli Lilly and Co
NYSE:LLY
64.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.5
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.1
32%
0.8
CH
Novartis AG
SIX:NOVN
16.5
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.1
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.7
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average EV/EBITDA: 395.5
17.8
2%
8.9
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.8
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FI
O
Orion Oyj
OMXH:ORNBV
Average EV/EBIT: 1 698.7
17.8
6%
3
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.6
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.1
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.5
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.5
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
10%
1

See Also

Summary
ORNBV intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORNBV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORNBV stock valuation using valuation multiples.
Wall Street Estimates
ORNBV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORNBV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.